Stakeholder Perspectives of the Inflation Reduction Act’s (2022) Impact on Prescription Drugs

Simple item page
dc.contributor.authorLieneck, Cristian
dc.contributor.authorMcLauchlan, Matthew
dc.contributor.authorAdachi, Valerie
dc.contributor.authorBillings, Roger
dc.date.accessioned2024-04-04T20:15:48Z
dc.date.available2024-04-04T20:15:48Z
dc.date.issued2024-03
dc.description.abstractIN this review, we examine the impact of the Inflation Reduction Act (IRA) of 2022 on pharmaceutical drugs in the United States, drawing on a diverse range of sources to understand the perceptions of multiple stakeholders and professionals. Findings suggest that the Act, while aiming to control price inflation, has had a multifaceted impact on the pharmaceutical sector.
dc.description.departmentHealth Administration
dc.description.departmentBusiness
dc.formatImage
dc.format.extent1 page
dc.format.medium1 file (.pdf)
dc.identifier.citationLieneck, C., McLauchlan, M., Adachi, V., & Billings, R. (2024). Stakeholder perspectives of the Inflation Reduction Act’s (2022) impact on prescription drugs. Poster presented at the Health Scholar Showcase, Translational Health Research Center, San Marcos, Texas.
dc.identifier.urihttps://hdl.handle.net/10877/18397
dc.language.isoen
dc.sourceHealth Scholar Showcase, 2024, Texas State University Translational Health Science Center, San Marcos, Texas, United States.
dc.subjectInflation Reduction Act
dc.subjectprescription drugs
dc.titleStakeholder Perspectives of the Inflation Reduction Act’s (2022) Impact on Prescription Drugs
dc.typePoster

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Lieneck, Cristian Stakeholder Perspectives.pdf
Size:
820.63 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.56 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Health Scholar Showcase